Kuros Biosciences has received clearance from the US Food and Drug Administration (FDA) for its MagnetOs Flex Matrix for expanded spinal indications. According to a press release issued by the company, MagnetOs Flex Matrix is now the third new innovation within the MagnetOs product family to be authorized by the USFDA in the past seven months. Previously, the USFDA has cleared MagnetOs Granules, MagnetOs Putty and MagnetOs Easypack Putty for use in the spine.
According to Kuros, MagnetOs Flex Matrix is a new form of bone graft for use with various bone marrow aspirates, which are the cells taken from the patient’s bone marrow. The product offers excellent granule retention, extremely high wickability and absorbs up to ten times more BMA (bone marrow aspirate) than other bone grafts. The product can be shaped to fill bony voids in any desired way. According to Kuros CEO Joost de Bruijn, the clearances help to reduce the risk of commercialization plans in the USA as the product is now available to spinal surgeons who mix their bone graft with bone marrow aspirate.
Kuros Biosciences AG is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH).
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com